Epidemiological studies suggest that both moderate and severe hypertriglyceridemia are associated with increased long term cardiovascular risk and mortality. Interestingly, the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention (REDUCE-IT) randomized trial recently enrolled 8179 statin-treated patients with elevated triglycerides levels (135mg/dL and <500mg/dL) and either established cardiovascular disease or diabetes plus at least one risk factor, and demonstrated that high dose (4 g/day) of icosapent ethyl reduced the risk of ischemic events, including cardiovascular death (1). Indeed, the secondary prevention cohort represented 70.7% of the total cohort, which experienced a lower rate of the key secondary efficacy composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke as compared to the placebo group (12.5% vs 16.9% HR:0.72, 95%CI (0.63-0.82).